Translational researches in schizophrenia have revealed the many aspects of biological evidence for schizophrenia. To find the intracellular signaling pathway responsible for antipsychotic medications, metabolic adverse events induced by atypical antipsychotics can provide a window to look for the novel molecular target mediating the therapeutic action of antipsychotics. Mammalian target of rapamycin (mTOR) is master switch regulating protein translation through sensing cellular energy state. Akt and mitogen activated protein kinase (MAPK) pathways cooperatively regulate mTOR signal pathway. In addition, AMP-activated protein kinase (AMPK), another major metabolic sensor maintaining metabolic homeostasis, interacts with mTOR to regulate the cellular response to various stimuli. Recent studies have suggested that mTOR signal pathway is involved in mood and psychotomimetic behavioral changes as well as epileptogenesis. In this talk, involvement of mTOR and AMPK signal pathways in the therapeutic and pathogenetic mechanisms of psychotic disorders will be reviewed and discussed based on the recent findings. Using support vector machine learning and pattern detection analysis, we demonstrate that the different kinds of at risk states (early at risk state, versus late at risk state) are associated with different kinds of brain alterations. It is possible to predict the risk of transition to psychosis on an individual level with high sensivity and specivity. This pattern recognition analyses proved also to be useful to differentiate between schizophrenia and depression (MDD) using brain aging as intermediate parameter. Title: Perspectives of tDCS in the treatment of affective disorders Abstract Major Depressive Disorder (MDD) is an incapacitating condition associated with significant personal, social and economic impairment. Nearly 30% of patients present drug refractoriness, reinforcing the need to develop novel therapeutic strategies for MDD. Transcranial direct current stimulation (tDCS) might be an alternative for these patients considering its tolerability, portability and ease of use. The tDCS technique alters neuronal resting membrane potentials to facilitate (anodal) and inhibit (cathodal) neuronal firing rates. The antidepressant effects of tDCS are based on neuroimaging studies, which have shown that, in depression, the left dorsolateral prefrontal cortex (DLPFC) is hypoactive and the right DLPFC is hyperactive. To achieve antidepressant effects, anodal tDCS is delivered over the left region for depolarization and cathodal tDCS is delivered over the right DLPFC for hyperpolarization. In this presentation, we review putative tDCS antidepressant mechanisms as well as clinical evidence based on recent controlled studies and meta-analyses evaluating tDCS efficacy and predictors of response for MDD. Present evidence indicates that tDCS may be an effective treatment strategy for MDD. There are no studies specifically examining the efficacy of tDCS in bipolar depression and mania, which are urgently needed in order to address tDCS effectiveness for bipolar disorder. In addition, there are reports of hypomania/mania after or during tDCS treatment; this risk should be prospectively investigated in further studies.
Speaker 4: Hans-Jürgen Möller, Germany
Title: Signatures from neuroimaging studies predict transition to psychosis Möller HJ, Koutsouleris N, Meisenzahl EM, Falkai P Abstract Currently in the field of schizophrenia research the early detection of at risk mental states for psychosis is an important topic of clinical research. Beside clinical and neuropsychological parameters structual MRI related parameters in focus.
Using support vector machine learning and pattern detection analysis, we demonstrate that the different kinds of at risk states (early at risk state, versus late at risk state) are associated with different kinds of brain alterations. It is possible to predict the risk of transition to psychosis on an individual level with high sensivity and specivity. This pattern recognition analyses proved also to be useful to differentiate between schizophrenia and depression (MDD) using brain aging as intermediate parameter. Title: Perspectives of tDCS in the treatment of affective disorders Abstract Major Depressive Disorder (MDD) is an incapacitating condition associated with significant personal, social and economic impairment. Nearly 30% of patients present drug refractoriness, reinforcing the need to develop novel therapeutic strategies for MDD. Transcranial direct current stimulation (tDCS) might be an alternative for these patients considering its tolerability, portability and ease of use. The tDCS technique alters neuronal resting membrane potentials to facilitate (anodal) and inhibit (cathodal) neuronal firing rates. The antidepressant effects of tDCS are based on neuroimaging studies, which have shown that, in depression, the left dorsolateral prefrontal cortex (DLPFC) is hypoactive and the right DLPFC is hyperactive. To achieve antidepressant effects, anodal tDCS is delivered over the left region for depolarization and cathodal tDCS is delivered over the right DLPFC for hyperpolarization. In this presentation, we review putative tDCS antidepressant mechanisms as well as clinical evidence based on recent controlled studies and meta-analyses evaluating tDCS efficacy and predictors of response for MDD. Present evidence indicates that tDCS may be an effective treatment strategy for MDD. There are no studies specifically examining the efficacy of tDCS in bipolar depression and mania, which are urgently needed in order to address tDCS effectiveness for bipolar disorder. In addition, there are reports of hypomania/mania after or during tDCS treatment; this risk should be prospectively investigated in further studies.
Speaker 2: Tae Young Lee, Republic of Korea
Title: Transcranial direct current stimulation in schizophrenia: a systemic review and meta-analysis Abstract Transcranial direct current stimulation (tDCS) has been proposed as a novel treatment options for in patients with schizophrenia. Several studies have investigate regarding the efficacy of tDCS intervention, but results were inconsistent. Therefore, meta-analytic conclusion is needed to evaluate the prospectives of this new intervention. Oline literature retrieval was conducted using Pubmed, Web of Science and Cochrane Central Register of Controlled Trials databases from January 2003 to October 2015. Key words were "tDCS", "transcranial direct current stimulation", and "schizophrenia". Eighteen studies addressing tDCS for treatment of schizophrenia were screened. We will investigate the pooled effect size of tDCS on schizophrenia and elaborate the effectiveness of tDCS as a novel treatment option.
Speaker 3: Sohee Park, USA
Title: Innovative approaches to enhancing prefrontal functions: brain stimulation, neuroplasticity-based cognitive training and music.
